Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

Weekly Picks

SILO logo
Silo Pharma
CM
CMCVentures
Community Contributor

Groundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s

Key Takeaways Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis (MS). The company’s unique approach of combining traditional drugs with psychedelic-inspired therapies positions it to address significant gaps in the treatment landscape.
View narrative
US$6.20
FV
86.8% undervalued intrinsic discount
234.00%
Revenue growth p.a.
7users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
7 days ago author updated this narrative
DOCN logo
DigitalOcean Holdings
NE
Nenad
Community Contributor

DigitalOcean Will Grow 14% by Embracing AI with Paperspace Acquisition

1. Current Business (Present Narrative): DigitalOcean is a cloud computing provider focused on small and medium-sized businesses (SMBs) , startups, and developers.
View narrative
US$50.00
FV
43.5% undervalued intrinsic discount
18.62%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
4 months ago author updated this narrative

Community Investing Ideas

Load previous narratives
IVVD logo
Invivyd
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Key Takeaways The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs. Efforts to engage with the scientific community and regulators may restore trust, enhancing future earnings and market potential.
View narrative
US$6.60
FV
92.0% undervalued intrinsic discount
173.47%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
6 days ago author updated this narrative
NEU logo
Neuren Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

Key Takeaways Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings. International expansion and R&D investments present significant long-term growth and valuation opportunities.
View narrative
AU$24.97
FV
49.5% undervalued intrinsic discount
-12.12%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
42users have followed this narrative
6 days ago author updated this narrative
ROOT logo
Root
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts

Expansive Costs Will Undermine Future Profitability In US Insurance

Key Takeaways Strategic investments in marketing and data science might boost future growth but will likely increase short-term expenses and pressure net margins. Reducing insurance rates in select states may drive customer growth but risks impacting net margins if policy volumes don't rise.
View narrative
US$105.20
FV
31.0% overvalued intrinsic discount
12.54%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
6 days ago author updated this narrative